SS
AMLX icon

SBI Securities’s Amylyx Pharmaceuticals AMLX Stock Holding History

SBI Securities’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18 Hold
1
– – ﹤0.01% 3860
2026
Q1 		$14 Hold
1
– – ﹤0.01% 3806
2025
Q4 		$12 Sell
1
-1,250
-100% -$17K ﹤0.01% 3848
2025
Q3 		$17K Buy
1,251
+1,250
+125,000% +$11.8K ﹤0.01% 1522
2025
Q2 		$6 Hold
1
– – ﹤0.01% 4048
2025
Q1 		$4 Hold
1
– – ﹤0.01% 4037
2024
Q4 		$4 Buy
+1
New +$5 ﹤0.01% 4003

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SBI Securities's AMLX Position: Q2 2026 in Review

SBI Securities held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 1 share worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #3860.

SBI Securities first reported a position in AMLX in Q4 2024 and has held it in 7 quarters since. The position peaked at $17K in Q3 2025. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • SBI Securities held 1 share of Amylyx Pharmaceuticals worth $18 as of Q2 2026.
  • SBI Securities left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
  • Amylyx Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3860 holding.
  • SBI Securities first reported a position in Amylyx Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Amylyx Pharmaceuticals position peaked at $17K in Q3 2025.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.